Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
American Journal of Clinical Dermatology
Published in: American Journal of Clinical Dermatology 5/2020

01-10-2020 | Vulgar Psoriasis | Leading Article

Progress to Date in Advancing Stratified Medicine in Psoriasis

Authors: Claire Reid, Lis Cordingley, Richard B. Warren, Christopher E. M. Griffiths

Published in: American Journal of Clinical Dermatology | Issue 5/2020

Login to get access

Abstract

Stratified medicine is the tailoring of treatment to the individual characteristics of each patient. This is a challenging task in the context of psoriasis, a complex disease with a variety of phenotypic presentations and a comorbidity burden that extends beyond cutaneous manifestations. In recent years, considerable progress has been made in understanding the immunology of psoriasis, and this has informed the development of increasingly precise and efficacious therapies. However, not all patients respond to biologic therapy, and access is limited to patients with moderate to severe disease. However, subpopulations of patients are emerging with distinct patterns of response to therapy, largely determined by clinical and pharmacogenomic factors. Despite progress to date, the natural history of psoriasis remains poorly understood. It is likely that disease onset, progression, development of comorbidities and response to therapy are due to a combination of genetic, inflammatory and environmental factors. We envision that a greater understanding of the natural history of psoriasis will be a key factor in progressing a stratified medicine approach to patient care, as will earlier intervention in the course of the disease.
Literature
1.
Radtke MA, Langenbruch A, Jacobi A, Schaarschmidt ML, Augustin M. Patient benefits in the treatment of psoriasis: long-term outcomes in German routine care 2007–2014. J Eur Acad Dermatol Venereol. 2016;30:1829–33.PubMed
2.
Kurd S, Troxel A, Crits-Christoph P, Gelfand J. The risk of depression, anxiety and suicidality in patients with psoriasis: a population-based cohort study. Arch Dermatol. 2010;146:891–5.PubMedPubMedCentral
3.
Parisi R, Rutter MK, Lunt M, Young HS, Symmons DPM, Griffiths CEM, et al. Psoriasis and the risk of major cardiovascular events: cohort study using the clinical practice research datalink. J Invest Dermatol. 2015;135:2189–97.PubMed
4.
Basko-Plluska J, Petronic-Rosic V. Psoriasis: epidemiology, natural history, and differential diagnosis. Psoriasis Targets Ther. 2012;2:67–766.
5.
Cole M, Jones C, Todd I. A new anti-estrogenic agent in late breast cancer. An early clinical appraisal of ICI46474. Br J Cancer. 1971;25:270–5.PubMedPubMedCentral
6.
Ran D, Cai M, Zhang X. Genetics of psoriasis: a basis for precision medicine. Precis Clin Med. 2019;2:120–30.
7.
Dand N, Satveer K, Capon F, Smith CH, Simpson MA, Barker JN. Psoriasis and Genetics. Acta Dermato Venereol. 2020;100:54–64.
8.
Trembath R, Clough R, Rosbotham J, Jone A, Camp R, Frodsham A, et al. Identification of a major susceptibility locus on chromosome 6p and evidence for further disease loci revealed by a two stage genome-wide search in psoriasis. Hum Mol Genet. 1997;6:813–20.PubMed
9.
Li K, Huang C, Randazzo B, Li S, Szapary P, Curran M, et al. HLA-C*06:02 allele and response to IL-12/23 inhibition: results from the ustekinumab phase 3 psoriasis program. J Invest Dermatol. 2016;136:2364–71.PubMed
10.
van Vugt L, van den Reek J, Coenen M, de Jong E. A systematic review of pharmacogenetic studies on the response to biologics in patients with psoriasis. Br J Dermatol. 2018;178:86–94.PubMed
11.
Dand N, Duckworth M, Baudry D, Russell A, Curtis CJ, Lee SH, et al. HLA-C*06:02 genotype is a predictive biomarker of biologic treatment response in psoriasis. J Allergy Clin Immunol. 2019;143:2120–30.PubMed
12.
Talamonti M, Galluzzo M, Zangrilli A, Papoutsaki M, Egan C, Bavetta M, et al. HLA-C*06:02 does not predispose to clinical response following long-term adalimumab treatment in psoriatic patients: a retrospective cohort study. Mol Dagnosis Ther. 2017;21:295–301.
13.
Carraro L, Malara G, Bartezaghi M, Flori ML, Costanzo A, Bianchi L, et al. Secukinumab shows high efficacy irrespective of HLA-Cw6 status in patients with moderate-to-severe plaque-type psoriasis: SUPREME study. Br J Dermatol. 2018;179:1072–80.PubMed
14.
Bachelez H. Pustular psoriasis: the dawn of a new era. Acta Derm Venereol. 2020;100:87–92.
15.
Robinson A, Van Voorhees A, Hsu S, Korman N, Lebwohl M, Bebo BJ, et al. Treatment of pustular psoriasis: from the Medical Board of the National Psoriasis Foundation. J Am Acad Dermatol. 2012;67:279–88.PubMed
16.
Bachelez H, Choon S, Marrakchi S, Burden A, Tsai T, Morita A, et al. Inhibition of the interleukin-36 pathway for the treatment of generalized pustular psoriasis. New Engl J Med. 2019;7:981–3.
17.
18.
National Institute for Health and Clinical Excellence Guideline. Psoriasis : assessment and management. Clinical Guideline. Published 24 October 2012. Available at nice.org.uk/guidance/cg153. Accessed 5 Mar 2020
19.
Okada Y, Han B, Tsoi L, Stuart P, Ellinghaus E, Tejasvi T, et al. Fine mapping major histocompatibility complex associations in psoriasis and its clinical subtypes. Am J Hum Genet. 2014;95:162–72.PubMedPubMedCentral
20.
Bowes J, Ashcroft J, Dand N, Jalali-Najafabadi F, Bellou E, Ho P, et al. Cross-phenotype association mapping of the MHC identifies genetic variants that differentiate psoriatic arthritis from psoriasis. Ann Rheum Dis. 2017;76:1774–9.PubMedPubMedCentral
21.
Patrick MT, Stuart PE, Raja K, Gudjonsson JE, Tejasvi T, Yang J, et al. Genetic signature to provide robust risk assessment of psoriatic arthritis development in psoriasis patients. Nat Commun. 2018;9:1–10.
22.
Lu Y, Chen H, Nikamo P, Low HQ, Helms C, Seielstad M, et al. Association of cardiovascular and metabolic disease genes with psoriasis. J Invest Dermatol. 2013;133:836–9.PubMed
23.
Koch M, Baurecht H, Ried JS, Rodriguez E, Schlesinger S, Volks N, et al. Psoriasis and cardiometabolic traits: modest association but distinct genetic architectures. J Invest Dermatol. 2015;135:1283–93.PubMedPubMedCentral
24.
Greb JE, Goldminz A, Eder JT, Lebwohl MG, Gladman DD, Wu JJ, et al. Psoriasis. Nat Rev Dis Primers. 2016;2:1–17.
25.
26.
Boyman O, Conrad C, Tonel G, Gilliet M, Nestle F. The pathogenic role of tissue-resident immune cells in psoriasis. Trends Immunol. 2007;28:51–7.PubMed
27.
Matos T, Malley J, Lowry E, Hamm D, Kirsch I, Robins H, et al. Clinically resolved psoriatic lesions contain psoriasis-specific IL-17-producing αβ T cell clones. J Clin Invest. 2017;127:4031–41.PubMedPubMedCentral
28.
Iversen L, Eidsmo L, Austad J, de Rie M, Osmancevic A, Skov L, et al. Secukinumab treatment in new-onset psoriasis: aiming to understand the potential for disease modification-rationale and design of the randomized, multicenter STEPIn study. J Eur Acad Dermatol Venereol. 2018;32:1930–9.PubMed
29.
Gallais Sérézal I, Classon C, Cheuk S, Barrientos-Somarribas M, Wadman E, Martini E, et al. Resident T cells in resolved psoriasis steer tissue responses that stratify clinical outcome. J Invest Dermatol. 2018;138:1754–63.PubMed
30.
Coates LC, Moverley AR, McParland L, Brown S, Navarro-Coy N, O’Dwyer JL, et al. Effect of tight control of inflammation in early psoriatic arthritis (TICOPA): a UK multicentre, open-label, randomised controlled trial. Lancet. 2015;386:2489–98.PubMedPubMedCentral
31.
Haroon M, Gallagher P, FitzGerald O. Diagnostic delay of more than 6 months contributes to poor radiographic and functional outcome in psoriatic arthritis. Ann Rheum Dis. 2015;74:1045–50.PubMed
32.
Smolen JS, Landewé R, Bijlsma J, Burmester G, Chatzidionysiou K, Dougados M, et al. EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2016 update. Ann Rheum Dis. 2017;76:960–77.PubMed
33.
Danese S, Fiorino G, Peyrin-Biroulet L. Early intervention in Crohn’s disease: towards disease modification trials. Gut. 2017;66:2179–87.PubMed
34.
Smith C, Jabbar-Lopez J, Yiu Z, Bale T, Burden A, Coates L, et al. British Association of Dermatologists guidelines for biologic therapy for psoriasis 2017. Br J Dermatol. 2016;38:42–9.
35.
Warren RB, Smith CH, Yiu ZZN, Ashcroft DM, Barker JNWN, Burden AD, et al. Differential drug survival of biologic therapies for the treatment of psoriasis: a prospective observational cohort study from the British Association of Dermatologists Biologic Interventions Register (BADBIR). J Invest Dermatol. 2015;135:2632–40.PubMed
36.
Reich K, Griffiths C, Gordon K, Papp K, Song M, Randazzo B, et al. Maintenance of clinical response and consistent safety profile with up to 3 years of continuous treatment with guselkumab: results from the VOYAGE 1 and VOYAGE 2 trials. J Am Acad Dermatol. 2020;82:936–45.PubMed
37.
38.
Vanderpuye-Orgle J, Zhao Y, Lu J, Shrestha A, Sexton A, Seabury S, et al. Evaluating the economic burden of psoriasis in the United States. J Am Acad Dermatol. 2015;72:961–7.PubMed
39.
40.
Menter MA, Griffiths CEM. Psoriasis: the future. Dermatol Clin. 2015;33:161–6.PubMed
41.
Reid C, Mason K, Esse S, McElhone K, Lunt M, Cordingley L, et al. Baseline characteristics of patients registering to British Association of Dermatologists Biologics and Immunomodulators Register stratified by disease duration at the time of registration. Br J Dermatol. 2019;181(Suppl S1):47.
42.
Garcia-Doval I, Carretero G, Vanaclocha F, Ferrandiz C, Dauden E, Sanchez-Carazo JL, et al. Risk of serious adverse events associated with biologic and nonbiologic psoriasis systemic therapy: patients ineligible versus eligible for randomized controlled trials. Arch Dermatol. 2012;148:463–70.PubMed
43.
Mason KJ, Barker JNWN, Smith CH, Hampton PJ, Lunt M, McElhone K, et al. Comparison of drug discontinuation, effectiveness, and safety between clinical trial eligible and ineligible patients in BADBIR. JAMA Dermatol. 2018;154:581–8.PubMedPubMedCentral
44.
Griffiths CEM, Barnes MR, Burden AD, Nestle FO, Reynolds NJ, Smith CH, et al. Establishing an Academic-Industrial Stratified Medicine Consortium: psoriasis stratification to optimize relevant therapy. J Invest Dermatol. 2015;135:2903–7.PubMed
45.
Tsakok T, Wilson N, Dand N, Loeff FC, Bloem K, Baudry D, et al. Association of serum ustekinumab levels with clinical response in psoriasis. JAMA Dermatol. 2019;155:1235–43.PubMedCentral
46.
Wilkinson N, Tsakok T, Dand N, Bloem K, Duckworth M, Baudry D, et al. Defining the therapeutic range for adalimumab and predicting response in psoriasis: a multicenter prospective observational cohort study. J Invest Dermatol. 2019;139:115–23.PubMedPubMedCentral
47.
Strober B, Ryan C, van der Kerkhof P, van der Walt J, Kimball A, Barker J, et al. Re-categorisation of psoriasis severity: Delphi consensus from the International Psoriasis Council. J Am Acad Dermatol. 2020;82:117–22.PubMed
48.
Thorneloe R, Griffiths C, Emsley R, Ashcroft D, Cordingley L, Groups, and on behalf of the BADBIR, and PSORT study groups. Intentional and unintentional medication non-adherence in psoriasis: the role of patients’ medication beliefs and habit strength. J Invest Dermatol. 2018;138:785–94.PubMedPubMedCentral
49.
Nelson PA, Kane K, Pearce CJ, Bundy C, Chisholm A, Hilton R, et al. “New to me”: Changing patient understanding of psoriasis and identifying mechanisms of change. The Pso Well® patient materials mixed-methods feasibility study. Br J Dermatol. 2017;177:758–70.PubMedPubMedCentral
50.
Chisholm A, Nelson PA, Pearce CJ, Littlewood AJ, Kane K, Henry AL, et al. Motivational interviewing-based training enhances clinicians’ skills and knowledge in psoriasis: findings from the Pso Well® study. Br J Dermatol. 2017;176:677–86.PubMed
51.
Burden AD, Warren RB, Kleyn CE, McElhone K, Smith CH, Reynolds NJ, et al. The British Association of Dermatologists’ Biologic Interventions Register (BADBIR): Design, methodology and objectives. Br J Dermatol. 2012;166:545–54.PubMed
52.
Warren RB, Marsden A, Tomenson B, Mason KJ, Soliman MM, Burden AD, et al. Identifying demographic, social and clinical predictors of biologic therapy effectiveness in psoriasis: a multicentre longitudinal cohort study. Br J Dermatol. 2018;180:1–8.
53.
Iskandar I, Ashcroft D, Warren R, Lunt M, McElhone K, Smith C, et al. Comparative effectiveness of biologic therapies on improvements in quality of life in patients with psoriasis. Br J Dermatol. 2017;177:1412–21.
54.
Richer V, Roubille C, Fleming P, Starnino T, McCourt C, McFarlane A, et al. Psoriasis and smoking: a systematic literature review and meta-analysis with qualitative analysis of effect of smoking on psoriasis severity. J Cutan Med Surg. 2016;20:221–7.PubMed
55.
Aune D, Snekvik I, Schlesinger S, Norat T, Riboli E, Vatten LJ. Body mass index, abdominal fatness, weight gain and the risk of psoriasis: a systematic review and dose–response meta-analysis of prospective studies. Eur J Epidemiol. 2018;33:1163–78.PubMedPubMedCentral
56.
Brenaut E, Horreau C, Pouplard C, Barnetche T, Paul C, Richard MA, et al. Alcohol consumption and psoriasis: a systematic literature review. J Eur Acad Dermatology Venereol. 2013;27(suppl. 3):30–5.
57.
Svanström C, Lonne-Rahm S-B, Nordlind K. Psoriasis and alcohol. N Z Med J. 2019;9:75–9.
58.
59.
Ford A, Siegel M, Bagel J, Cordoro K, Garg A, Gottlieb A, et al. Dietary recommendations for adults with psoriasis or psoriatic arthritis from the Medical Board of the National Psoriasis Foundation: a systematic review. JAMA Dermatol. 2018;154:934–50.PubMed
60.
Majeed-Ariss R, McPhee M, McAteer H, Griffiths C, Young H. The top 10 research priorities for psoriasis in the UK: results of a James Lind Alliance psoriasis Priority Setting Partnership. Br J Dermatol. 2019;181:871–3.PubMedPubMedCentral
61.
Kimball AB, Gieler U, Linder D, Sampogna F, Warren R, Augustin M. Psoriasis: is the impairment to a patient’s life cumulative? J Eur Acad Dermatol Venereol. 2010;24:989–1004.PubMed
62.
Linder M, Piaserico S, Augustin M, Belloni Fortina A, Cohen AD, Gieler U, et al. Psoriasis—the life course approach. Acta Dermatol Venereol. 2016;96(Suppl 217):102–8.
63.
Ding WY, Beresford MW, Saleem MA, Ramanan AV. Big data and stratified medicine: what does it mean for children? Arch Dis Child. 2019;104:389–94.PubMed
64.
Sagner M, McNeil A, Puska P, Auffray C, Price ND, Hood L, et al. The P4 Health Spectrum—A Predictive Preventive, Personalized and Participatory Continuum for Promoting Healthspan. Prog Cardiovasc Dis. 2017;59:506–21.PubMed
Metadata
Title
Progress to Date in Advancing Stratified Medicine in Psoriasis
Authors
Claire Reid
Lis Cordingley
Richard B. Warren
Christopher E. M. Griffiths
Publication date
01-10-2020
Publisher
Springer International Publishing
Published in
American Journal of Clinical Dermatology / Issue 5/2020
Print ISSN: 1175-0561
Electronic ISSN: 1179-1888
DOI
https://doi.org/10.1007/s40257-020-00533-z

Other articles of this Issue 5/2020

American Journal of Clinical Dermatology 5/2020 Go to the issue

Review Article

Primary Cutaneous Coccidioidomycosis: An Update

Short Communication

Botulinum Toxin Type B for Hidradenitis Suppurativa: A Randomised, Double-Blind, Placebo-Controlled Pilot Study

Original Research Article

Acne Keloidalis Nuchae and the Metabolic Syndrome: A Population-Based Study

Original Research Article

Development of Clinician-Reported Outcome (ClinRO) and Patient-Reported Outcome (PRO) Measures for Eyebrow, Eyelash and Nail Assessment in Alopecia Areata

Review Article

Bedside Diagnostics for Infections: A Guide for Dermatologists

Review Article

Vitiligo and Melanoma-Associated Vitiligo: Understanding Their Similarities and Differences